The Oncology Institute, Inc. was formed in 2007 as a collection of community oncology practices in southern California and has grown into a national organization focused on lowering the cost of oncology care while maintaining high quality treatment. The company provides physician services, infusion therapy, radiation therapy, outpatient blood product transfusions and around the clock patient support through its affiliated physician practices. It also operates under value…
The Oncology Institute, Inc. was formed in 2007 as a collection of community oncology practices in southern California and has grown into a national organization focused on lowering the cost of oncology care while maintaining high quality treatment. The company provides physician services, infusion therapy, radiation therapy, outpatient blood product transfusions and around the clock patient support through its affiliated physician practices. It also operates under value based agreements with payors, runs specialty and retail pharmacies that fill oral and injectable medications for oncology patients, and manages clinical trial and palliative care programs. As of December 31 2025 the firm operated sixty five clinics owned by affiliated physicians, eighty one independently owned clinics under contract and a network of one hundred ninety eight unaffiliated providers, serving a total of approximately two million patients under value based arrangements across seventeen markets in five states including California Arizona Nevada Florida and Oregon.
The company generates revenue from several sources. In its fee for service business it bills for physician and infusion services using CPT codes and for drugs on a cost plus basis, collecting a small patient co pay at the time of service and seeking reimbursement from commercial and government managed care programs. Under value based contracts it receives prospective payments such as fixed per member per month amounts or gain or loss sharing arrangements from payors including Medicare Advantage Medicaid and commercial insurers, and retains profit when the cost of care for the enrolled population is below the agreed payment. In 2025 more than forty six percent of total revenue came from value based contracts. The specialty pharmacy division fills medication orders that are not administered in the clinic and bills pharmacy benefit managers, usually collecting a patient co pay at pickup. Clinical trial services are billed to pharmaceutical companies or contract research organizations based on the procedures performed on enrolled patients. All revenue streams are supported by the company’s technology platform and its relationships with provider networks.
The Oncology Institute, Inc. positions itself as a leader in value based oncology care in the United States. It differentiates from traditional oncology practices that rely mainly on fee for service reimbursement by offering a hybrid model that combines owned clinics with a broad network of independent providers, allowing it to manage risk and coordinate care across multiple sites. The company competes with large oncology groups such as American Oncology Network, US Oncology Network and OneOncology, as well as with specialty benefit managers like Evolent Health, Thyme Care and OncoHealth. Its competitive advantages include long standing relationships with major payors such as Anthem, CareMore Health, Heritage Provider Network and Optum Care, a disciplined focus on evidence based pathways aligned with National Comprehensive Cancer Network guidelines, and a technology infrastructure that standardizes care delivery and supports risk adjustment. The firm notes that its largest customer by revenue in 2025 represented approximately fourteen percent of patient services revenue, indicating limited concentration risk. These strengths enable the firm to achieve lower total costs while maintaining or improving clinical outcomes and patient satisfaction.
The company serves adult and senior patients who require medical oncology hematology and related care. Its customers include individuals covered by Medicare Advantage plans, traditional Medicare, Medicaid and commercial insurance policies. The firm works closely with referring physicians and hospitals that send patients upon diagnosis. Specific payor partners named in the filing are Anthem, CareMore Health, Heritage Provider Network and Optum Care, and the company notes that more than half of its 2025 revenue came from value based contracts where these payors have designated it as their preferred or exclusive oncology provider. In addition to direct patient care, the specialty pharmacy and clinical trial divisions serve patients who need oral medications or access to investigational therapies, broadening the overall customer base beyond the clinic setting. As of the end of 2025 the firm managed approximately two million patients under value based agreements, reflecting the scale of its population health responsibilities.
Sectors:Healthcare · Consumer StaplesSector rationaleThe company's primary business is providing medical oncology and hematology services, including infusion therapy, radiation therapy, and physician services, which falls under Healthcare Services. It also operates specialty and retail pharmacies to fill medications for oncology patients, which is a distinct business line categorized under Consumer Staples (Pharmacies).Industries:Healthcare ServicesHealthcarePrimaryThe company operates a network of oncology clinics providing physician services, infusion therapy, and radiation therapy in an outpatient setting. It generates revenue through fee-for-service billing for these procedures and value-based payments from payers for managing outpatient cancer care.PharmaciesConsumer StaplesSecondaryThe company operates specialty and retail pharmacies that fill oral and injectable medications for oncology patients, billing pharmacy benefit managers and collecting patient co-pays.Contract ResearchHealthcareSecondaryThe company manages clinical trial programs and bills pharmaceutical companies or contract research organizations for procedures performed on enrolled patients.Classified using BQ-MICSCIK: 0001799191
Investment Thesis
▲ Bull case
The Oncology Institute (TOI) is executing a high-margin, scalable growth strategy centered on delegated capitation in Florida, where profitability has already been achieved at the 4-wall EBITDA level despite being in an early expansion phase. With plans to expand delegated capitation to cover 200,000 Medicare Advantage lives across 25 counties by Q3 FY26—up from approximately 90,000 in Q1 FY26—the company is rapidly scaling a model that targets an 85% Medical Loss Ratio (MLR), which is currently performing slightly better than target. This outperforms industry peers like Evolent Health, which reported an MLR of 93%, suggesting TOI’s hybrid employed-network care delivery model, tight clinical pathway adherence, and provider portal-driven engagement are creating a structural cost advantage. The upcoming launch of the proprietary provider portal in Q3 FY26 will extend Part D dispensing access to MSO providers, unlocking incremental revenue outside current guidance and leveraging the existing Specialty Pharmacy infrastructure, which delivered 78% year-over-year revenue growth and 19.2% gross margin in Q1 FY26. These initiatives are not merely incremental but represent a flywheel effect: each new delegated life increases prescription volume, improves pharmacy utilization, and enhances data for AI-driven operational efficiencies—already on track to deliver $2 million in OpEx savings in FY26 with further upside anticipated in care navigation and prior authorization by 2028. The market is underestimating how these integrated components—capitation expansion, pharmacy capture, AI automation, and provider engagement—will compound to drive sustainable margin expansion beyond the current guidance range of $0 to $9 million in adjusted EBITDA for FY26, especially as deductible-related seasonality diminishes and scale improves operating leverage.
TOI’s Specialty Pharmacy business is emerging as a hidden catalyst for long-term profitability and differentiation, with Q1 FY26 performance revealing strengths not fully reflected in current guidance. The division generated $87.5 million in revenue and $16.8 million in gross profit, driven by a 103% increase in prescription fills—far outpacing the 12% decline in average revenue per fill—indicating that volume growth, not pricing, is the primary engine. This volume surge is being fueled by both organic patient growth and improved attachment rates from provider education and workflow optimizations, which exceeded internal expectations. Critically, the pharmacy’s gross margin remained flat at 19.2% year-over-year despite macroeconomic headwinds like the Inflation Reduction Act’s phase-in, proving the resilience of TOI’s procurement strategy, formulary pathways via TOI Pathways, and central clinical infrastructure. The company is actively expanding pharmacy access to delegated network members in Florida in H2 FY26—a move not included in annual revenue guidance—which will allow it to capture Part D scripts from capitated lives currently routed to external pharmacies, reducing leakage and increasing capture rates. With the provider portal enabling e-prescribing and formulary visibility for MSO providers by H2 FY26, TOI is positioned to monetize its pharmacy platform across both employed and contracted networks, transforming it from a captive dispensing arm into a broader distribution engine. This capability, combined with the clinic expansion plan (7 new TOI clinics by year-end), creates a vertically integrated care model that competitors relying on fragmented networks cannot easily replicate, and the market is failing to price in the incremental contribution of this integrated pharmacy capability to future EBITDA and free cash flow.
The company’s financial trajectory is being materially improved by operational initiatives that are underappreciated in current guidance, particularly the $20 million year-over-year increase in free cash flow outlook despite unchanged adjusted EBITDA and gross margin guidance. This improvement stems from successful vendor renegotiations—especially on the drug supply chain—where TOI is leveraging its growing scale to secure better pricing and terms, a benefit that will compound as delegated lives and pharmacy volume increase. Operating cash flow turned less negative in Q1 FY26 (-$2.3 million vs. -$5.0 million in Q1 FY25), reflecting early traction from these initiatives, and the company now expects full-year FY26 free cash flow of $5 million to $15 million, up from a prior outlook of -$15 million to +$5 million. This shift is not driven by one-time events but by structural improvements in procurement, AI-enabled revenue cycle management, and prior authorization automation—areas where TOI has already launched pilots and is scaling rapidly. The $2 million in OpEx savings from AI initiatives in revenue cycle, prior auth, and call center is described by management as “scratching the surface,” with substantial additional upside anticipated in care navigation and labor-intensive programs like high-value cancer care by 2028. These efficiency gains, combined with improving operating leverage as revenue scales (41% YoY growth in Q1 FY26), are lowering the break-even point for profitability and creating a buffer against macroeconomic volatility. The market is overlooking how these behind-the-scenes operational enhancements are derisking the path to sustainable positive EBITDA and free cash flow, making the current guidance conservative relative to the company’s execution trajectory.
The Oncology Institute (TOI) is executing a high-margin, scalable growth strategy centered on delegated capitation in Florida, where profitability has already been achieved at the 4-wall EBITDA level despite being in an early expansion phase. With plans to expand delegated capitation to cover 200,000 Medicare Advantage lives across 25 counties by Q3 FY26—up from approximately 90,000 in Q1 FY26—the company is rapidly scaling a model that targets an 85% Medical Loss Ratio (MLR), which is currently performing slightly better than target. This outperforms industry peers like Evolent Health, which reported an MLR of 93%, suggesting TOI’s hybrid employed-network care delivery model, tight clinical pathway adherence, and provider portal-driven engagement are creating a structural cost advantage. The upcoming launch of the proprietary provider portal in Q3 FY26 will extend Part D dispensing access to MSO providers, unlocking incremental revenue outside current guidance and leveraging the existing Specialty Pharmacy infrastructure, which delivered 78% year-over-year revenue growth and 19.2% gross margin in Q1 FY26. These initiatives are not merely incremental but represent a flywheel effect: each new delegated life increases prescription volume, improves pharmacy utilization, and enhances data for AI-driven operational efficiencies—already on track to deliver $2 million in OpEx savings in FY26 with further upside anticipated in care navigation and prior authorization by 2028. The market is underestimating how these integrated components—capitation expansion, pharmacy capture, AI automation, and provider engagement—will compound to drive sustainable margin expansion beyond the current guidance range of $0 to $9 million in adjusted EBITDA for FY26, especially as deductible-related seasonality diminishes and scale improves operating leverage.
TOI’s Specialty Pharmacy business is emerging as a hidden catalyst for long-term profitability and differentiation, with Q1 FY26 performance revealing strengths not fully reflected in current guidance. The division generated $87.5 million in revenue and $16.8 million in gross profit, driven by a 103% increase in prescription fills—far outpacing the 12% decline in average revenue per fill—indicating that volume growth, not pricing, is the primary engine. This volume surge is being fueled by both organic patient growth and improved attachment rates from provider education and workflow optimizations, which exceeded internal expectations. Critically, the pharmacy’s gross margin remained flat at 19.2% year-over-year despite macroeconomic headwinds like the Inflation Reduction Act’s phase-in, proving the resilience of TOI’s procurement strategy, formulary pathways via TOI Pathways, and central clinical infrastructure. The company is actively expanding pharmacy access to delegated network members in Florida in H2 FY26—a move not included in annual revenue guidance—which will allow it to capture Part D scripts from capitated lives currently routed to external pharmacies, reducing leakage and increasing capture rates. With the provider portal enabling e-prescribing and formulary visibility for MSO providers by H2 FY26, TOI is positioned to monetize its pharmacy platform across both employed and contracted networks, transforming it from a captive dispensing arm into a broader distribution engine. This capability, combined with the clinic expansion plan (7 new TOI clinics by year-end), creates a vertically integrated care model that competitors relying on fragmented networks cannot easily replicate, and the market is failing to price in the incremental contribution of this integrated pharmacy capability to future EBITDA and free cash flow.
The company’s financial trajectory is being materially improved by operational initiatives that are underappreciated in current guidance, particularly the $20 million year-over-year increase in free cash flow outlook despite unchanged adjusted EBITDA and gross margin guidance. This improvement stems from successful vendor renegotiations—especially on the drug supply chain—where TOI is leveraging its growing scale to secure better pricing and terms, a benefit that will compound as delegated lives and pharmacy volume increase. Operating cash flow turned less negative in Q1 FY26 (-$2.3 million vs. -$5.0 million in Q1 FY25), reflecting early traction from these initiatives, and the company now expects full-year FY26 free cash flow of $5 million to $15 million, up from a prior outlook of -$15 million to +$5 million. This shift is not driven by one-time events but by structural improvements in procurement, AI-enabled revenue cycle management, and prior authorization automation—areas where TOI has already launched pilots and is scaling rapidly. The $2 million in OpEx savings from AI initiatives in revenue cycle, prior auth, and call center is described by management as “scratching the surface,” with substantial additional upside anticipated in care navigation and labor-intensive programs like high-value cancer care by 2028. These efficiency gains, combined with improving operating leverage as revenue scales (41% YoY growth in Q1 FY26), are lowering the break-even point for profitability and creating a buffer against macroeconomic volatility. The market is overlooking how these behind-the-scenes operational enhancements are derisking the path to sustainable positive EBITDA and free cash flow, making the current guidance conservative relative to the company’s execution trajectory.
The Oncology Institute (TOI) faces significant execution risk in its Florida delegated capitation expansion, as the company is attempting to scale a complex risk-bearing model across 25 counties and 200,000 lives by Q3 FY26 without fully disclosing the health plan partners or providing granular data on medical expense trends beyond MLR performance. While management claims the delegated book is performing slightly better than the 85% target MLR, they offered no clarity on absolute medical expense trends, risk adjustment accuracy, or how they are managing potential adverse selection as they onboard lives from multiple major carriers—information that is critical given that Evolent Health, operating in similar markets, reported a 93% MLR. The lack of transparency raises concerns that TOI may be underestimating future medical costs, particularly as newer, less mature contracts ramp up and the company assumes risk for populations with potentially higher comorbidity burdens. Furthermore, the claim of 4-wall EBITDA profitability in Florida is based on an allocation methodology that may not fully capture the true cost of scaling infrastructure, including the planned opening of 7 new clinics and expansion of the MSO provider network—expenses that could erode reported profitability if utilization or enrollment lags. The company’s reliance on unverified internal metrics and avoidance of third-party benchmarks suggests the market may be ignoring the potential for MLR deterioration as scale increases, which would directly undermine the economics of the delegated model and delay the path to sustainable profitability.
TOI’s Specialty Pharmacy business, while showing strong top-line growth, is vulnerable to external pricing pressures and contractual risks that are not being adequately addressed in management’s commentary, despite the division contributing 59.4% of total revenue in Q1 FY26. Although gross margin held steady at 19.2% year-over-year, this stability came amid a 12% decline in average revenue per fill, signaling a shifting mix toward lower-reimbursement drugs or increased use of generics and biosimilars—a trend that could accelerate as the Inflation Reduction Act’s drug pricing provisions fully take effect. The company’s ability to maintain margin depends heavily on its procurement function and distributor relationships, yet it provided no detail on contract longevity, rebate exposure, or vulnerability to PBM pressure, all of which could compress margins if drug pricing reforms intensify. Additionally, the pharmacy’s current restriction to oncology-specific medications limits its ability to capture broader outpatient scripts from patients with comorbidities, and while management hinted at future expansion into ancillary services like clinical trials and care navigation via the provider portal, these remain unguided and speculative. The expectation that the portal will enable Part D fills through MSO providers by H2 FY26 is contingent on provider adoption, e-prescribing integration, and formulary buy-in—factors that are uncertain and not reflected in current financial projections. Without clearer visibility into sustainable unit economics beyond oncology scripts or contractual safeguards against pricing volatility, the market may be overestimating the pharmacy’s role as a durable, high-margin growth engine.
TOI’s outlook remains heavily dependent on the successful implementation and adoption of AI-driven operational efficiencies, yet the company provided no concrete timeline, metrics, or financial commitments beyond the initial $2 million in OpEx savings for FY26, raising concerns that these initiatives may not deliver the scale of benefits implied by management’s optimistic long-term commentary. While Rob Carter acknowledged that the $2 million forecast is “scratching the surface” and anticipates further savings in care navigation and prior authorization by 2028, the long-range forecast issued in January explicitly did not contemplate additional AI efficiencies, indicating a lack of formal modeling or confidence in realizing those gains. This disconnect between aspirational statements and concrete planning suggests the market may be pricing in efficiencies that are not yet de-risked, particularly given the company’s history of seasonal adjusted EBITDA losses in Q1 and its reliance on improving operating leverage to reach full-year profitability. Furthermore, the company’s liquidity position—ending Q1 FY26 with $30.3 million in cash and $85.9 million in senior secured convertible notes maturing in August 2027—creates refinancing risk, especially if free cash flow generation lags or if vendor renegotiations fail to deliver the expected $20 million improvement in cash flow. The market may be overlooking the execution risk inherent in scaling technology, clinic expansion, and provider network integration simultaneously, particularly in a capital-intensive, regulation-heavy industry where delays in AI rollout, portal adoption, or clinic openings could quickly erode the assumed operating leverage and push profitability further into the future.
The Oncology Institute (TOI) faces significant execution risk in its Florida delegated capitation expansion, as the company is attempting to scale a complex risk-bearing model across 25 counties and 200,000 lives by Q3 FY26 without fully disclosing the health plan partners or providing granular data on medical expense trends beyond MLR performance. While management claims the delegated book is performing slightly better than the 85% target MLR, they offered no clarity on absolute medical expense trends, risk adjustment accuracy, or how they are managing potential adverse selection as they onboard lives from multiple major carriers—information that is critical given that Evolent Health, operating in similar markets, reported a 93% MLR. The lack of transparency raises concerns that TOI may be underestimating future medical costs, particularly as newer, less mature contracts ramp up and the company assumes risk for populations with potentially higher comorbidity burdens. Furthermore, the claim of 4-wall EBITDA profitability in Florida is based on an allocation methodology that may not fully capture the true cost of scaling infrastructure, including the planned opening of 7 new clinics and expansion of the MSO provider network—expenses that could erode reported profitability if utilization or enrollment lags. The company’s reliance on unverified internal metrics and avoidance of third-party benchmarks suggests the market may be ignoring the potential for MLR deterioration as scale increases, which would directly undermine the economics of the delegated model and delay the path to sustainable profitability.
TOI’s Specialty Pharmacy business, while showing strong top-line growth, is vulnerable to external pricing pressures and contractual risks that are not being adequately addressed in management’s commentary, despite the division contributing 59.4% of total revenue in Q1 FY26. Although gross margin held steady at 19.2% year-over-year, this stability came amid a 12% decline in average revenue per fill, signaling a shifting mix toward lower-reimbursement drugs or increased use of generics and biosimilars—a trend that could accelerate as the Inflation Reduction Act’s drug pricing provisions fully take effect. The company’s ability to maintain margin depends heavily on its procurement function and distributor relationships, yet it provided no detail on contract longevity, rebate exposure, or vulnerability to PBM pressure, all of which could compress margins if drug pricing reforms intensify. Additionally, the pharmacy’s current restriction to oncology-specific medications limits its ability to capture broader outpatient scripts from patients with comorbidities, and while management hinted at future expansion into ancillary services like clinical trials and care navigation via the provider portal, these remain unguided and speculative. The expectation that the portal will enable Part D fills through MSO providers by H2 FY26 is contingent on provider adoption, e-prescribing integration, and formulary buy-in—factors that are uncertain and not reflected in current financial projections. Without clearer visibility into sustainable unit economics beyond oncology scripts or contractual safeguards against pricing volatility, the market may be overestimating the pharmacy’s role as a durable, high-margin growth engine.
TOI’s outlook remains heavily dependent on the successful implementation and adoption of AI-driven operational efficiencies, yet the company provided no concrete timeline, metrics, or financial commitments beyond the initial $2 million in OpEx savings for FY26, raising concerns that these initiatives may not deliver the scale of benefits implied by management’s optimistic long-term commentary. While Rob Carter acknowledged that the $2 million forecast is “scratching the surface” and anticipates further savings in care navigation and prior authorization by 2028, the long-range forecast issued in January explicitly did not contemplate additional AI efficiencies, indicating a lack of formal modeling or confidence in realizing those gains. This disconnect between aspirational statements and concrete planning suggests the market may be pricing in efficiencies that are not yet de-risked, particularly given the company’s history of seasonal adjusted EBITDA losses in Q1 and its reliance on improving operating leverage to reach full-year profitability. Furthermore, the company’s liquidity position—ending Q1 FY26 with $30.3 million in cash and $85.9 million in senior secured convertible notes maturing in August 2027—creates refinancing risk, especially if free cash flow generation lags or if vendor renegotiations fail to deliver the expected $20 million improvement in cash flow. The market may be overlooking the execution risk inherent in scaling technology, clinic expansion, and provider network integration simultaneously, particularly in a capital-intensive, regulation-heavy industry where delays in AI rollout, portal adoption, or clinic openings could quickly erode the assumed operating leverage and push profitability further into the future.